Can semaglutide make you infertile — separating the concern from the evidence

The myth worth correcting first: 'Wegovy causes infertility'

This claim appears regularly in online forums and on social media, often presented as settled fact. It is not. No regulatory body (not the MHRA, not the EMA, not the FDA) has identified infertility as a known effect of semaglutide. The large-scale trials that led to Wegovy's UK licence tracked adverse events carefully across thousands of participants, and reproductive harm was not among the findings.

Where the concern likely comes from is a conflation of two different things: the genuine precautionary guidance around pregnancy and conception, and normal physiological changes that accompany substantial weight loss. Both are real; neither is the same as the medicine damaging a person's capacity to conceive.

Sorting out these threads matters, because acting on the wrong version of this information could mean someone avoids a treatment that might genuinely help their health, or alternatively takes it without the reproductive safeguards that do apply. Our Wegovy overview sets out the full licence picture for context.

Why weight loss itself can temporarily change menstrual patterns

When body weight drops meaningfully (through any route, including diet, surgery or medication) the hormonal environment shifts. Oestrogen, which is partly stored in fat tissue, changes in availability. The hypothalamic-pituitary-ovarian axis that regulates the menstrual cycle is sensitive to energy balance. The practical result is that some women experience cycle irregularity, a change in flow, or temporarily absent periods during active weight loss.

This is well-documented physiology, not a semaglutide side effect. The same pattern appears after bariatric surgery and with rapid dietary restriction. Cycles typically stabilise once weight levels off. Crucially, irregular periods do not mean ovulation has stopped entirely, which is why unintended pregnancy is a real possibility for women on weight-loss treatment, not a reduced one.

The NHS England guidance on weight-management injections touches on exactly this point: effective contraception is advised throughout treatment, not because conception becomes impossible but because it may happen unexpectedly, and semaglutide should not be taken during pregnancy.

A quick habit worth building: if your cycle changes noticeably in the first few months of treatment, note the dates in your phone's health app. A clear pattern over two or three cycles gives a prescriber something concrete to work with at review.

The contraception question, and what it means for semaglutide users

Here is where the guidance becomes specific and practical. Semaglutide slows gastric emptying as part of its mechanism. For women taking an oral contraceptive pill, this raises a theoretical concern: if the pill moves through the stomach more slowly, its absorption could be altered. The current advice, reflected in semaglutide's prescribing information, is to use an additional non-oral method of contraception (condoms, for instance) as a precaution while on Wegovy.

This is not evidence that Wegovy reduces fertility or makes the pill ineffective in every case. It is a sensible precautionary measure given that the medicine is contraindicated in pregnancy and that the interaction, while modest, is not yet fully characterised across all formulations. A prescriber can advise on the most appropriate approach for your specific contraceptive method.

The separate question of whether semaglutide might, for some people with obesity-related hormonal disruption, improve fertility conditions is genuinely interesting, and actively studied. Weight loss in people with conditions like polycystic ovary syndrome can restore ovulatory function. Whether semaglutide has a direct positive effect on fertility beyond weight reduction remains an area of ongoing research rather than established clinical fact.

What the precautionary guidance actually says, and why it is not the same as 'it causes infertility'

The MHRA and Novo Nordisk's prescribing information are clear: semaglutide should not be used during pregnancy, while breastfeeding, or during the period when someone is actively trying to conceive. A wash-out period before attempting conception is recommended. This guidance exists because the medicine's effects on a developing pregnancy have not been fully studied, not because it is known to damage reproductive capacity. It is also worth noting that not all semaglutide products share the same manufacturer, and anyone weighing their options can read about the Eli Lilly semaglutide offering to understand how the branded choices compare.

The distinction matters. 'We do not know it is safe in pregnancy' is the right reason to stop treatment before trying to conceive. It is a different statement from 'it prevents you conceiving'. The first is a standard precaution applied to many prescription medicines; the second is unsupported by the current evidence base.

If you are considering whether semaglutide is appropriate for your situation and have questions about your reproductive plans, that conversation should happen with a prescriber before treatment starts, not after. It is one of the reasons clinical assessment before any prescription is not just a regulatory box-tick. A related question that sometimes arises at this stage is whether semaglutide can be made or sourced outside licensed channels, something a prescriber can address clearly during consultation. Our free consultation gives you direct access to a GPhC-registered prescriber who reviews each case personally, it is a reasonable place to raise this kind of question.